Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic
O'Bryant SE, Mielke MM, Rissman RA, Lista S, Vanderstichele H, Zetterberg H, Lewczuk P, Posner H, Hall J, Johnson L, Fong YL, Luthman J, Jeromin A, Batrla-Utermann R, Villarreal A, Britton G, Snyder PJ, Henriksen K, Grammas P, Gupta V, Martins R, Hampel H (2017)
Publication Type: Journal article
Publication year: 2017
Journal
Book Volume: 13
Pages Range: 45-58
Journal Issue: 1
DOI: 10.1016/j.jalz.2016.09.014
Abstract
The last decade has seen a substantial increase in research focused on the identification of blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based biomarkers have significant advantages of being time- and cost-efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood-based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public-private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.
Authors with CRIS profile
Involved external institutions
AXA Research Fund
France (FR)
Edith Cowan University
Australia (AU)
University of North Texas (UNT)
United States (USA) (US)
Instituto de Investigaciones Científicas y Servicios de Alta Tecnología AIP (INDICASAT AIP)
Panama (PA)
Quanterix Corporation
United States (USA) (US)
Brown University
United States (USA) (US)
University of Rhode Island
United States (USA) (US)
ADx NeuroSciences
Belgium (BE)
Sahlgrenska University Hospital / Sahlgrenska Universitetssjukhuset
Sweden (SE)
University of California, San Diego
United States (USA) (US)
Johnson & Johnson Services, Inc.
United States (USA) (US)
Roche Diagnostics (Schweiz) AG
Switzerland (CH)
Mayo Clinic
United States (USA) (US)
Pfizer, Inc.
United States (USA) (US)
Nordic Bioscience A/S
Denmark (DK)
France (FR)
Edith Cowan University
Australia (AU)
University of North Texas (UNT)
United States (USA) (US)
Instituto de Investigaciones Científicas y Servicios de Alta Tecnología AIP (INDICASAT AIP)
Panama (PA)
Quanterix Corporation
United States (USA) (US)
Brown University
United States (USA) (US)
University of Rhode Island
United States (USA) (US)
ADx NeuroSciences
Belgium (BE)
Sahlgrenska University Hospital / Sahlgrenska Universitetssjukhuset
Sweden (SE)
University of California, San Diego
United States (USA) (US)
Johnson & Johnson Services, Inc.
United States (USA) (US)
Roche Diagnostics (Schweiz) AG
Switzerland (CH)
Mayo Clinic
United States (USA) (US)
Pfizer, Inc.
United States (USA) (US)
Nordic Bioscience A/S
Denmark (DK)
How to cite
APA:
O'Bryant, S.E., Mielke, M.M., Rissman, R.A., Lista, S., Vanderstichele, H., Zetterberg, H.,... Hampel, H. (2017). Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers & Dementia, 13(1), 45-58. https://dx.doi.org/10.1016/j.jalz.2016.09.014
MLA:
O'Bryant, Sid E., et al. "Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic." Alzheimers & Dementia 13.1 (2017): 45-58.
BibTeX: Download